Clinical outcomes in recurrent glioblastoma with oncolytic virotherapy: a review

Key Points

• Oncolytic virotherapy shows promising tumor response rates in patients with recurrent glioblastoma, indicating a potential treatment option.
• Clinical outcomes reveal improved survival rates for individuals treated with oncolytic virotherapy compared to standard therapies.
• Review of multiple studies demonstrates significant immune response activation in patients, contributing to enhanced treatment effectiveness.
• Findings call for further research on combining oncolytic virotherapy with other treatments to maximize clinical benefits in glioblastoma.